Buy & Sell Crown Castle International Corp (CCI) – Crown Castle International Corp Price Today
Aura AI Summary
Key Stats
- $38.11BMarket Cap
- Real EstateSector
- -16.22%3M Drawdown
- $67.93BEnterprise Value
- 4.87%Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 94 daysTypical Hold Time
Crown Castle International Corp (CCI) is currently valued at a market capitalization of $38.11B, with an enterprise value of $67.93B. Over the past 52 weeks, Crown Castle International Corp has traded between a low of $76.96 and a high of $113.91, highlighting its annual price range. Over the past three months, Crown Castle International Corp has recorded a drawdown of -16.22%, reflecting recent price volatility. Crown Castle International Corp offers a dividend yield of 4.87%, with the most recent dividend of $1.06 paid on 13 Mar 26. On average, investors hold Crown Castle International Corp for approximately 94 days, indicating typical investor behavior on the platform.
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Most Recent News
Investigation launched into Alphatec Holdings over possible securities law violations after Q1 earnings miss.
Glancy Prongay Wolke & Rotter LLP has started a securities fraud investigation into Alphatec Holdings following the company's Q1 2026 earnings report, which missed revenue estimates and lowered its full-year outlook. Alphatec reported lower deliverie...
Cancer centers rush to enroll patients in Revolution Medicines' pancreatic cancer drug after positive trial results.
Revolution Medicines received FDA approval for an expanded access program for its pancreatic cancer drug, daraxonrasib, following positive Phase 3 trial results showing significant survival benefits. The drug demonstrated a median overall survival of...
SaintQuant launches AI crypto trading bots amid Bitcoin surge and rising institutional interest
SaintQuant has officially launched its AI-driven quantitative crypto trading platform, offering retail investors easy, no-code access to automated trading strategies. This launch coincides with Bitcoin surpassing $82,000 and record institutional infl...